Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influsplit SSW · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Influsplit SSW® | BIOLOGICAL | - |
Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return, and follow-up visits) should be enrolled in the study. * All Subjects, enrolled in this study, must not been immunized agains...
Influsplit SSW is an investigational monoclonal antibody being developed for influenza, a viral infection of the respiratory tract. It is currently in Phase 3 clinical development, meaning it has not yet been approved and is still being studied for safety and effectiveness.
Influsplit SSW is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the drug's potential as a treatment for influenza.
Influsplit SSW is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and efficacy for treating influenza.
Influsplit SSW has one completed Phase 3 clinical trial with the identifier NCT00306943, titled 'Annual Study for Fluarix Registration.' This trial enrolled 120 participants with influenza in Germany and included healthy volunteers aged 18 years and older.
Influsplit SSW is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for influenza. The drug has completed one clinical trial, but it remains under study and has not yet received regulatory approval.